Tag:
Avastin
Latest Headlines
Latest Headlines
Biomarkers rescue Amgen's MAb, support Roche's Avastin
Studies give boost to Genentech/Roche's ($RHHBY) Avastin (bevacizumab) and Amgen's ($AMGN) rilotumumab.
Counterfeit drugs threaten strides against malaria
While it is the discovery of counterfeit Avastin that is drawing the headlines, the vast majority of counterfeit drugs are being pawned off on the poor in undeveloped areas of Asia and Africa. While victims there pay the health cost, there is an indirect cost to developed countries that often underwrite efforts to eradicate disease in the undeveloped world.
ASCO data to shine new light on Pfizer, Roche, J&J drugs
Cancer drug aficionados, rejoice. A slew of new studies goes public later today, as drugmakers gear up for next month's American Society of Clinical Oncology meeting.
Top 10 Best-selling Cancer Drugs in 2011
Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.
Novartis may weigh Lucentis price cut in U.K.
Last week, data comparing that product to its close cousin, Avastin, in macular degeneration patients found the two meds roughly equivalent, efficacy-wise. This week, a U.K study concluded that the two offered similar results with a similar safety profile.
Novartis digs into safety data in Avastin-vs.-Lucentis study
According to the company's analysis, Avastin patients had a 30% higher risk of serious systemic side effects than Lucentis patients did.
Avastin, Lucentis equally effective at improving vision, big study finds
More fuel for the Avastin-vs-Lucentis debate: A big U.S. government study of the two drugs deemed them more or less equivalent for treating age-related macular degeneration.
Novartis wants U.K. to quash off-label Avastin use
Novartis is taking up arms against British eye doctors who use Roche's Avastin.
FDA warns 56 more docs of fake Avastin supplies
The agency notified the physicians and clinics in 13 states about the counterfeits and warned them not to use the products.
Roche sales flat for Q1, but cancer meds shine
Roche's first-quarter numbers were hardly earth-shaking: Sales eroded 1%, partly because of the strong Swiss franc.
